JAZZ Q2 2023 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$957M+2.6% YoY

Gross Profit

$860M89.8% margin

Operating Income

$158M16.5% margin

Net Income

$104M10.9% margin

EPS (Diluted)

$1.52

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$297M

Free Cash Flow

$291M

Stock-Based Comp.

$61M

Balance Sheet

Total Assets

$11.3B

Total Liabilities

$7.7B

Stockholders' Equity

$3.5B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$957M	$933M	+2.6%
Gross Profit	$860M	$809M	+6.3%
Operating Income	$158M	$86M	+84.3%
Net Income	$104M	$35M	+201.3%

Revenue Segments

Xywav

$327M34%

Epidiolex/Epidyolex

$202M21%

Xyrem

$160M17%

Rylaze/Enrylaze

$102M11%

Zepzelca

$70M7%

Defitelio/Defibrotide

$46M5%

Vyxeos

$34M4%

High Sodium AG Oxybate Product Royalty Revenue

$6M1%

Other Royalty And Contract Revenues

$5M1%

Other Products

$3M0%

Sativex

$3M0%

Geographic Segments

UNITED STATES

$885M92%

Europe

$59M6%

Other Countries

$13M1%